Lung cancer in Brazil

Araujo, Luiz H.; Carvalho, Heloísa A.; Terra, Ricardo Mingarini

doi:10.1590/s1806-37562017000000135

Cited by 80 publications

(107 citation statements)

References 47 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the registry of malignant neoplasms in the state of São Paulo, only 1,835 (8.8%) of the 20,850 lung cancer patients registered between 2000 and 2010 had stage I disease. (11,12) That difference can be explained by the fact that our sample was composed of highly selected patients treated surgically at public and private referral hospitals, where they had greater access to chest CT scans and lung cancer screening programs.…”

Section: Discussionmentioning

confidence: 99%

Robotic thoracic surgery for non-small cell lung cancer: initial experience in Brazil

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective: To describe the morbidity, mortality, and rate of complete resection associated with robotic surgery for the treatment of non-small cell lung cancer in Brazil, as well as to report the rates of overall survival and disease-free survival in patients so treated. Methods: This was a retrospective study of patients diagnosed with non-small cell lung carcinoma and undergoing resection by robotic surgery at one of six hospitals in Brazil between February of 2015 and July of 2018. Data were collected retrospectively from the electronic medical records. Results: A total of 154 patients were included. The mean age was 65 ± 9.5 years (range, 30-85 years). The main histological diagnosis was adenocarcinoma, which was identified in 128 patients (81.5%), followed by epidermoid carcinoma, identified in 14 (9.0%). Lobectomy was performed in 133 patients (86.3%), and segmentectomy was performed in 21 (13.7%). The mean operative time was 209 ± 80 min. Postoperative complications occurred in 32 patients (20.4%). The main complication was air leak, which occurred in 15 patients (9.5%). The median (interquartile range) values for hospital stay and drainage time were 4 days (3-6 days) and 2 days (2-4 days), respectively. There was one death in the immediate postoperative period (30-day mortality rate, 0.5%). The mean follow-up period was 326 ± 274 days (range, 3-1,110 days). Complete resection was achieved in 97.4% of the cases. Overall mortality was 1.5% (3 deaths), and overall survival was 97.5%. Conclusions: Robotic pulmonary resection proved to be a safe treatment for lung cancer. Longer follow-up periods are required in order to assess long-term survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Robotic thoracic surgery for non-small cell lung cancer: initial experience in Brazil

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Brazil, there are no data about the current treatment given to patients with LA-NSCLC or about the efficacy of that treatment. 11 We decided to assess the effect of CC in Brazilian patients with stage III NSCLC treated in the routine clinical practice scenario in five cancer treatment institutions throughout Brazil.…”

Section: Introductionmentioning

confidence: 99%

Stage III Non–Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort

Lima

Baldotto

Barrios

et al. 2018

JGO

Self Cite

View full text Add to dashboard Cite

PurposeOf newly diagnosed patients with non–small-cell lung cancer (NSCLC), stage III accounts for 30%. Most patients are treated with concurrent chemoradiation therapy, but the addition of consolidation chemotherapy (CC) is debatable. We examined the effect of CC in Brazilian patients with stage III NSCLC treated in routine clinical practice.MethodsWe retrospectively collected data for patients from five different Brazilian cancer institutions who had stage III NSCLC and who were treated with chemoradiation therapy followed or not by CC. Eligible patients were age 18 years or older and must have been treated with cisplatin-carboplatin plus etoposide, paclitaxel, or vinorelbine, concurrently with thoracic radiation therapy (RT). Patients treated with surgery or neoadjuvant chemotherapy were excluded. The primary end point was overall survival (OS). Associations between CC and clinical variables and demographics were evaluated by using Pearson’s χ2 test. Survival curves were calculated by using the Kaplan-Meier method and were compared using the log-rank test. Univariable and multivariable analysis used a Cox proportional hazards model.ResultsWe collected data from 165 patients. Median age was 60 years. Most patients were male (69.1%), white (77.9%), current or former smokers (93.3%), and had stage IIIB disease (52.7%). Adenocarcinoma was the most common histology (47.9%). Weight loss of more than 5% was observed in 39.1% and Eastern Cooperative Oncology Group performance status of 2 was observed in 14.6%. The only variable associated with CC was T stage (P = .022). We observed no statistically significant difference in OS between patients treated or not with CC (P = .128). A total delivered RT dose ≥ 61 Gy was the only variable independently associated with improved survival (P = .012).ConclusionBrazilian patients with locally advanced NSCLC who were treated with standard treatment achieved OS similar to that reported in randomized trials. CC did not improve OS in patients with stage III NSCLC after concurrent chemoradiation therapy. An RT dose of less than 61 Gy had a negative effect on OS.

show abstract

“…In low- and middle-income countries, the enthusiasm for these novel treatments is tempered by the limited access to molecular tools to characterize tumors, as well as by the high costs of targeted therapies and immunotherapies. 9 As a result, a large proportion of patients continue to receive conventional (i.e., non-targeted) chemotherapy, which, in many circumstances, is associated with limited efficacy and significant adverse effects.…”

Section: Introductionmentioning

confidence: 99%

Molecular profile of non-small cell lung cancer in northeastern Brazil

Oliveira

Silva²,

Alves

et al. 2019

J. bras. pneumol.

View full text Add to dashboard Cite

Objective: To investigate the histological subtypes and mutational profiles of non-small cell lung cancer in Brazil, looking for correlations among histological subtypes, expression of anaplastic lymphoma kinase (ALK), EGFR mutation status, and programmed death-ligand 1 (PD-L1) expression. Methods: We evaluated 173 specimens obtained from patients with lung adenocarcinoma in northeastern Brazil. Expression of PD-L1 and ALK was evaluated by immunohistochemistry; EGFR mutation status was evaluated by sequencing. We categorized the histological subtypes in accordance with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Results: The most common histological subtypes of lung adenocarcinoma were solid predominant (in 46.8%), acinar predominant (in 37.0%), and lepidic predominant (in 9.8%). ALK expression was detected in 10.4% of the samples, and 22.0% of the tumors harbored EGFR mutations. The most common EGFR mutation was an exon 21 L858R point mutation (in 45.5%), followed by an exon 19 deletion (in 36.3%). The tumor proportion score for PD-L1 expression was ≥ 50% in 18.2% of the samples, 1-49% in 32.7%, and 0% in 49.5%. The solid predominant subtype was significantly associated with wild-type EGFR status (p = 0.047). Positivity for PD-L1 expression was not found to be significantly associated with ALK expression or EGFR mutation status. Conclusions: Our results suggest that the molecular profile of non-small cell lung cancer in northeastern Brazil differs from those of populations in other regions of the country, with ALK positivity being higher than the other biomarkers. Further studies including clinical and genetic information are required to confirm these differences, as well as studies focusing on populations living in different areas of the country.

show abstract

Lung cancer in Brazil

Cited by 80 publications

References 47 publications

Robotic thoracic surgery for non-small cell lung cancer: initial experience in Brazil

Robotic thoracic surgery for non-small cell lung cancer: initial experience in Brazil

Stage III Non–Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort

Molecular profile of non-small cell lung cancer in northeastern Brazil

Contact Info

Product

Resources

About